MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer.
Title | MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer. |
Publication Type | Journal Article |
Year of Publication | 2016 |
Authors | Gogas, H., Kotoula V., Alexopoulou Z., Christodoulou C., Kostopoulos I., Bobos M., Raptou G., Charalambous E., Tsolaki E., Xanthakis I., Pentheroudakis G., Koutras A., Bafaloukos D., Papakostas P., Aravantinos G., Psyrri A., Petraki K., Kalogeras K. T., Pectasides D., & Fountzilas G. |
Journal | J Transl Med |
Volume | 14 |
Issue | 1 |
Pagination | 136 |
Date Published | 2016 05 17 |
ISSN | 1479-5876 |
Keywords | Adult, Aged, Aged, 80 and over, Biomarkers, Tumor, Breast Neoplasms, Centromere, Chromosomal Instability, Cohort Studies, Enzyme Activation, Female, Gene Dosage, Humans, Middle Aged, Multivariate Analysis, Neoplasm Metastasis, Phosphatidylinositol 3-Kinases, Proportional Hazards Models, Proto-Oncogene Proteins c-myc, Receptor, ErbB-2, Survival Analysis, Trastuzumab, Treatment Outcome |
Abstract | BACKGROUND: There is an unmet need for more efficient patient stratification for receiving trastuzumab in the metastatic breast cancer (mBC) setting, since only part of such patients benefit from the addition of this agent to chemotherapy. The aim of this study was to investigate the prognostic value of biomarkers including MYC and MET in mBC patients treated with trastuzumab-based regimens. |
DOI | 10.1186/s12967-016-0883-z |
Alternate Journal | J Transl Med |
PubMed ID | 27184134 |
PubMed Central ID | PMC4869295 |